"Moderna and CARsgen Collaborate for Groundbreaking CAR-T Cell Therapy and mRNA Cancer Vaccine Combination"

Moderna and CARsgen have announced a collaboration to test CARsgen's Claudin18.2 CAR T-cell candidate, CT041, in combination with Moderna's investigational mRNA cancer vaccine. The collaboration will involve preclinical and Phase I studies. CT041 is already being investigated in various trials for gastric, pancreatic, and other digestive system cancers and has received Orphan Drug designation from the FDA in 2020 and Regenerative Medicine Advanced Therapy designation in 2022.